menu
    • menu
    [{"orgOrder":0,"company":"Triveni Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"TRIV-509","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Triveni Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Triveni Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Triveni Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"TRIV-509","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Triveni Bio","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Triveni Bio \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"12","companyTruncated":"Triveni Bio \/ Goldman Sachs Alternatives"}]

    Find Clinical Drug Pipeline Developments & Deals by Triveni Bio

    Menu

    Triveni Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Triveni Bio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Triveni Bio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRIV-509

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Goldman Sachs Alternatives

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Triveni Bio Raises $115M To Expand I&I Therapeutics Pipeline

                            Details : The financing aims to advance Triveni's lead product TRIV-509, KLK5/7 dual inhibitor, which is being evaluated for the treatment of atopic dermatitis.

                            Brand Name : TRIV-509

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : TRIV-509

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Goldman Sachs Alternatives

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Triveni Bio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Triveni Bio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRIV-509

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Atlas Venture

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for ...

                            Details : The financing will support the advancement of TRIV-509 from preclinical development to a Phase 2a clinical trial and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.

                            Brand Name : TRIV-509

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : TRIV-509

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Atlas Venture

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth